Allergy Therapeutics (AGY) Reaches New 1-Year Low at $24.00

Allergy Therapeutics plc (LON:AGY) reached a new 52-week low during trading on Wednesday . The stock traded as low as GBX 24 ($0.33) and last traded at GBX 25.50 ($0.36), with a volume of 11764 shares changing hands. The stock had previously closed at GBX 24.75 ($0.35).

Several equities research analysts recently commented on AGY shares. Numis Securities reaffirmed a “buy” rating and issued a GBX 45 ($0.63) price target on shares of Allergy Therapeutics in a report on Wednesday, January 31st. FinnCap reissued a “corporate” rating and set a GBX 47 ($0.66) target price on shares of Allergy Therapeutics in a research note on Wednesday, March 7th.

ILLEGAL ACTIVITY WARNING: This story was reported by WKRB News and is the sole property of of WKRB News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://www.wkrb13.com/2018/04/25/allergy-therapeutics-agy-reaches-new-1-year-low-at-24-00.html.

About Allergy Therapeutics

Allergy Therapeutics Plc is a pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum-free products. The Company’s segments are Central Europe, which includes segments, such as Germany, Australia, Switzerland and the Netherlands; Southern Europe, which includes Italy and Spain; the United Kingdom, and Rest of World.

Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply